Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a report issued on Saturday.

A number of other brokerages also recently issued reports on IMUX. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $12.67.

Immunic Price Performance

Shares of IMUX stock opened at $1.20 on Friday. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11. The stock’s 50 day simple moving average is $1.03 and its two-hundred day simple moving average is $1.26. The company has a market cap of $108.09 million, a PE ratio of -0.98 and a beta of 1.87.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after acquiring an additional 96,894 shares in the last quarter. Millennium Management LLC boosted its position in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares in the last quarter. Focus Partners Wealth boosted its position in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after purchasing an additional 23,610 shares in the last quarter. Bridgeway Capital Management LLC boosted its position in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares in the last quarter. Finally, 683 Capital Management LLC boosted its position in shares of Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after purchasing an additional 15,349 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.